Cinchonine exerts anti-tumor and immunotherapy sensitizing effects in lung cancer by impairing autophagic-lysosomal degradation

Currently, there are several treatments approaches available for lung cancer; however, patients who develop drug resistance or have poor survival rates urgently require new therapeutic strategies for lung Cancer. In Autophagy, damaged proteins or organelles are enclosed within autophagic vesicles with a bilayer membrane structure and transported to the lysosomes for degradation and recirculation. Autophagy is a crucial pathway involved in the clearance of Reactive Oxygen Species (ROS) and damaged mitochondria. Meanwhile, inhibiting Autophagy is a promising strategy for Cancer treatment. In this study, we found for the first time that Cinchonine (Cin) can act as an Autophagy suppressor and exert anti-tumor effects. Cin significantly inhibited the proliferation, migration, and invasion of Cancer cells in vitro and the tumor growth and metastasis in vivo, without obvious toxic effects. We found that Cin suppressed the autophagic process by blocking autophagosome degradation through the inhibition of the maturation of lysosomal hydrolases. Cin-mediated Autophagy inhibition resulted in the elevated ROS level and the accumulation of damaged mitochondria, which in turn promoted Apoptosis. N-acetylcysteine, a potential ROS scavenger, significantly suppressed Cin-induced Apoptosis. Additionally, Cin upregulated programmed death-ligand 1 (PD-L1) expression in lung Cancer cells by inhibiting Autophagy. Compared with monotherapy and control group, the combined administration of anti-PD-L1 antibody and Cin significantly reduced tumor growth. These results suggest that Cin exerts anti-tumor effects by inhibiting Autophagy, and that the combination of Cin and PD-L1 blockade has synergistic anti-tumor effects. The data demonstrates the significant clinical potential of Cin in lung Cancer treatment.

Autophagy; Cinchonine; Lung cancer; Lysosome; PD-L1.